Literature DB >> 10658113

Differential responses of collagen and glycosaminoglycan syntheses and cell proliferation to exogenous transforming growth factor beta 1 in the developing mouse skin fibroblasts in culture.

K Kishi1, H Nakajima, S Tajima.   

Abstract

Skin fibroblast cultures were established from mouse foetuses at days 14, 15, 16 and 18 of gestation and from newborn mice. Modulations of mitotic and biosynthetic phenotypes of the fibroblasts by transforming growth factor beta1 (TGFbeta1) were studied. Treatment of the fibroblasts with TGFbeta1 at doses of 1 and 10 ng/ml for 48 h resulted in significant stimulation of cell proliferation in the 15-, 16- and 18-day foetal fibroblasts and a slight stimulation in the 14-day foetal fibroblasts. Treatment with TGFbeta1 resulted in stimulation of collagen synthesis approximately 2-fold in the 18-day foetal and newborn fibroblasts, but failed to stimulate it in the 14-, 15- and 16-day foetal fibroblasts. TGFbeta1 stimulated glycosaminoglycan (GAG) synthesis throughout all developmental stages approximately 1.8-2.6 fold. Histological study demonstrated that skin wounds made at day 16 of gestation were replaced with normal-appearing dermis, but at day 18 the wounds left dermal fibrosis and lack of hair follicles. These results indicate that the modulations of fibroblast phenotypes (proliferation and syntheses of collagen and GAG) in response to TGFbeta1 occur at different stages of gestation. Ontogenic transitions of skin wound healing and collagen synthetic phenotype with TGFbeta1 treatment in cultured fibroblasts occurred between days 16 and 18 of gestation, suggesting that the unresponsiveness of collagen synthesis to exogenous TGFbeta1 in cell culture may be related to the phenomenon of scarless wounds in the foetus. Copyright 1999 The British Association of Plastic Surgeons.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10658113     DOI: 10.1054/bjps.1999.3163

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  6 in total

1.  Bone morphogenetic protein (BMP) signaling controls hair pigmentation by means of cross-talk with the melanocortin receptor-1 pathway.

Authors:  Andrey A Sharov; Michael Fessing; Ruzanna Atoyan; Tatyana Y Sharova; Carrie Haskell-Luevano; Lorin Weiner; Keiko Funa; Janice L Brissette; Barbara A Gilchrest; Vladimir A Botchkarev
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-23       Impact factor: 11.205

2.  IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis.

Authors:  Min Huang; Sherven Sharma; Li X Zhu; Michael P Keane; Jie Luo; Ling Zhang; Marie D Burdick; Ying Q Lin; Mariam Dohadwala; Brian Gardner; Raj K Batra; Robert M Strieter; Steven M Dubinett
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

3.  Treatment of Acute Wounds With Recombinant Human-Like Collagen and Recombinant Human-Like Fibronectin in C57BL/6 Mice Individually or in Combination.

Authors:  Yunqing Dong; Weidong Zhu; Xiaoxuan Lei; Xin Luo; Qi Xiang; Xuanru Zhu; Qiao Pan; Panshi Jin; Biao Cheng
Journal:  Front Bioeng Biotechnol       Date:  2022-05-19

4.  Defining the cellular repertoire of GPCRs identifies a profibrotic role for the most highly expressed receptor, protease-activated receptor 1, in cardiac fibroblasts.

Authors:  Aaron N Snead; Paul A Insel
Journal:  FASEB J       Date:  2012-08-02       Impact factor: 5.191

5.  Dynamic Expression of Novel MiRNA Candidates and MiRNA-34 Family Members in Early- to Mid-Gestational Fetal Keratinocytes Contributes to Scarless Wound Healing by Targeting the TGF-β Pathway.

Authors:  Feng Zhao; Zhe Wang; Hongxin Lang; Xiaoyu Liu; Dianbao Zhang; Xiliang Wang; Tao Zhang; Rui Wang; Ping Shi; Xining Pang
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

6.  Dermal fibroblasts derived from fetal and postnatal humans exhibit distinct responses to insulin like growth factors.

Authors:  Kerstin J Rolfe; Alison D Cambrey; Janette Richardson; Laurie M Irvine; Adriaan O Grobbelaar; Claire Linge
Journal:  BMC Dev Biol       Date:  2007-11-07       Impact factor: 1.978

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.